According to recent reports, the drug quality regulator in India is to ask companies carrying the drug rosiglitazone to add a serious warning to the packaging that makes patients and healthcare professionals aware of the potential risks to heart patients.
The American Diabetes Association and European Association for the study of Diabetes have both removed rosiglitazone from their lists of recommended drugs. The move has prompted the Drug Controller General of India to make the change.
A DCGI controller reportedly commented: “Rosiglitazone is under continuous focus of our pharmacovigilance expert committee. We are monitoring the drug. We have asked all manufacturers to print a warning on the label of all formulations containing rosiglitazone to caution heart patients against using the drug.”
As many as 30 different pharmaceutical companies in India currently market generic versions of the drug, as well as the inventor GlaxoSmithKline. The drug has faced falling sales following controversy in the last two years.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…